Recent Updates
Recently added Catalysts

Syndax Pharmaceuticals, Inc.

SNDXFDA catalysts, PDUFA dates & pipeline intelligence
$9.2
▲ +0.07 · +0.77%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full SNDX financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $9.0252W HIGH $25.59
Volume
2.60 M
Value Traded
24.02 M
Short % Float
23.12%
Days to Cover
6.4
-4.07%Week
-29.72%1 Month
-55.71%3 Month
-54.3%6 Month
+10.59%5 Year
+64.66%All Time

Cash Data

Unlock SNDX cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
828.26 M
EPS (TTM)
-2.33
P/E Ratio
-
Ent. Value
995.34 M
Total Shares
90.03 M
Float Shares
81.82 M
Insiders
9.12%
Institutions
113.40%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Phase 2 data presentation
Niktimvo (axatilimab-csfr)
Recurrent or refractory chronic graft-versus-host disease (cGVHD)
Priority
Phase 2BiologicsImmunology
Unlock every SNDX catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

SNDX Catalyst Timeline

Dated clinical, regulatory and corporate events for Syndax Pharmaceuticals, Inc.

Catalyst Timeline

Dated clinical, regulatory & corporate events for Syndax Pharmaceuticals, Inc.

515Total events
21Upcoming
123Tier-1 (high impact)
2016 to 2028Coverage

Upcoming catalysts 2

T1Topline Readout
Subscribe to view catalyst details
AxatilimabApproved
T2Oral Presentation
Subscribe to view catalyst details
RevumenibApproved

Event history 50

●Management ChangeCorporate
Inducement stock option grant of up to 270,000 shares to new CFO under NASDAQ Rule 5635(c)(4)
●Quarterly UpdateCorporate
Syndax reports third quarter 2026 financial results and business update
●Management ChangeCorporate
Announcement of hiring of Aaron A. Ondrey as CFO
▼Primary Endpoint MissedAxatilimabApprovedClinical Data
MAXPIRe missed primary endpoint of annualized rate of FVC decline
idiopathic pulmonary fibrosissource ↗
▲Safety Data UpdateAxatilimabApprovedClinical Data
Axatilimab well tolerated in MAXPIRe with no new safety signals
idiopathic pulmonary fibrosissource ↗
▼Program DiscontinuationAxatilimabApprovedCorporate
Syndax does not plan further development of axatilimab in IPF
idiopathic pulmonary fibrosissource ↗
▼Topline ReadoutAxatilimabApprovedClinical Data
MAXPIRe Phase 2 topline results in IPF announced
idiopathic pulmonary fibrosissource ↗
▼Program DiscontinuationAxatilimabApprovedCorporate
Syndax does not plan to move forward with further development of axatilimab in IPF
idiopathic pulmonary fibrosis (IPF)source ↗
▼Primary Endpoint MissedAxatilimabApprovedClinical Data
MAXPIRe Phase 2 trial of axatilimab in IPF did not meet primary endpoint
idiopathic pulmonary fibrosis (IPF)source ↗
●PublicationAxatilimabApprovedPresentation
Data supporting safety and feasibility of reduced-frequency axatilimab dosing published in Blood Advances
recurrent or refractory chronic graft-versus-host disease (GVHD)source ↗
Unlock the full SNDX catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How SNDX actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-10-12axatilimab Phase 2 topline data readout Phase 2
Unlock 14 more SNDX historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
3
Drugs Scored
rNPV / MCap
Top Drug
Top 13%
Micro Cap
(rank 95 of 725)
Percentile Rank
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Sep 2026; product lines: last four quarters to Sep 2026 (10-K and 10-Q))
ProductRevenuePrior periodChange
Revuforj
Showing 9 of 23 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
Revumenib Small MoleculesMarketedNCT06226571Acute Myeloid LeukemiaApproved ACTIVE NOT_RECRUITING 1,033Feb 1, 2027
Revumenib Small MoleculesMarketedNCT07563010Relapsed Adult AMLApproved NOT YET_RECRUITING 146Jun 1, 2031
Revumenib Small MoleculesNCT07923071Relapsed/Refractory (R/R) Hematologic MalignanciesPhase 1 NOT YET_RECRUITING 18Jan 1, 2032
Entinostat Small MoleculesCompletedNCT02437136Non-Small Cell Lung CancerPhase 1/2 COMPLETED 191Sep 29, 2022
Revumenib Small MoleculesMarketedNCT05406817Acute LeukemiaApproved COMPLETED 9Nov 18, 2024
Revumenib Small MoleculesMarketedNCT05326516Relapsed/Refractory LeukemiasApproved COMPLETED 30Jul 29, 2024
Axatilimab BiologicsMarketedNCT03604692Chronic Graft-versus-host-diseaseApproved COMPLETED 337Oct 18, 2024
Axatilimab BiologicsNCT06132256Idiopathic Pulmonary FibrosisPhase 2 COMPLETED 145Sep 10, 2026
Axatilimab BiologicsNot countedNCT03238027Solid TumorPhase 1 COMPLETED 45Nov 20, 2020
Unlock the SNDX pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every SNDX program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
revumenib
BreakthroughPriorityFast Track+1
acute myeloid leukemiaPhase 1b2026-11-04high rates of remission, MRD negativity, and encouraging survivalRead MoreSyndax Highlights Acceptance of 19 Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Abstracts, Including 7 for Oral Presentation, at ASH 2026Read More
Scroll for more · summaries link to the source press release
Unlock every SNDX trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock SNDX insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Podlesak DennisDirectorOption 8,000 247,763 held$11.81 10/29/2026
Unlock the full SNDX insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
Kynam Capital Management, LP 8.5 % (-12.4 %) 153.24 M 8.15 M 1.24% ( 100.00 K)
Unlock every fund holding SNDX
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in SNDX
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see SNDX ownership
Insider and institutional ownership, quarter by quarter.

SNDX Short Interest

Shares sold short, counted twice a month.

23.12%
Short % of Float
of tradable shares sold short
18.9M
Shares Sold Short
+5.1% vs prior count
6.4 High
Days to Cover
trading days of normal volume to buy every short share back
3.0M
Avg Daily Volume
the average used for days to cover
Unlock SNDX short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-11-20
Unlock SNDX option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live SNDX option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock SNDX options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How SNDX ranks across every disease it competes in

Competitive Position is a premium feature
See how SNDX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

SNDX News

SNDX
Nov 9, 2026
SNDXGeneral

Syndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Syndax Pharmaceuticals announced the hiring of Aaron A. Ondrey as CFO, effective November 9, 2026. He received an inducement award to purchase 270,000 shares at $9.55 each, vesting over four years. This award aligns with NASDAQ Listing Rule 5635(c)(4) and aims to support his long-term commitment to the company.

Read more →
SNDX
Nov 4, 2026
SNDXGeneral
▼ -10.3%on this newsshared move

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Syndax Pharmaceuticals announced the grant of inducement awards for 213,500 shares to five new employees under its 2023 Inducement Plan. The stock options will vest over four years, starting with 25% after one year. This move supports the company's commitment to advancing innovative cancer therapies.

Read more →
SNDX
Nov 4, 2026
SNDXConferences/Events
▼ -26.9%on this newsshared move

Syndax to Host ASH Investor Event in Person and via Webcast on December 14, 2026

Syndax Pharmaceuticals announced an investor event on December 14, 2026, during the ASH Annual Meeting. The event will feature discussions led by the management team and key opinion leaders on significant data presented at the meeting. A live webcast will also be available for those unable to attend in person.

Read more →
SNDX
Nov 4, 2026
SNDXConferences/Events
▼ -26.9%on this newsshared move

Syndax Highlights Acceptance of 19 Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Abstracts, Including 7 for Oral Presentation, at ASH 2026

Syndax Pharmaceuticals announced the acceptance of 19 abstracts for the ASH 2026 meeting, including 7 for oral presentation. The abstracts emphasize the promising activity of revumenib in various acute leukemia settings and the potential of axatilimab in chronic GVHD. The company will host an investor event on December 14, 2026, to discuss the findings.

Read more →
SNDX
Nov 2, 2026
SNDXGeneral
▲ +9.1%on this news· ran to -27% by day 3shared move

Syndax Reports Third Quarter 2026 Financial Results and Provides Business Update

Syndax Pharmaceuticals reported strong financial results for Q3 2026, with total revenue of $83.3 million, an 82% increase from the previous year. Revuforj (revumenib) and Niktimvo (axatilimab-csfr) contributed significantly to this growth, with net revenues of $60.7 million and $67.4 million, respectively. The company anticipates presenting new clinical data in Q4 2026 that could further enhance its market position.

Read more →
SNDX
Nov 2, 2026
SNDXGeneral
▲ +9.1%on this news· ran to -27% by day 3shared move

Syndax Announces CFO Transition – Aaron A. Ondrey Appointed Chief Financial Officer

Syndax Pharmaceuticals announced Aaron A. Ondrey as the new Chief Financial Officer, effective November 9, 2026. He succeeds Keith A. Goldan, who will retire but assist during the transition. Ondrey has over 25 years of experience in financial leadership within the biotechnology sector and is expected to enhance Syndax's financial strategy.

Read more →
SNDX
Oct 30, 2026
SNDXGeneral

Syndax’s Revuforj® (revumenib) Wins Prestigious 2026 Prix Galien USA Award for Best Product for Rare/Orphan Diseases

Syndax Pharmaceuticals announced that Revuforj (revumenib) won the 2026 Prix Galien USA Award for Best Product for Rare/Orphan Diseases. The drug is the first and only menin inhibitor approved for adults and children aged one year and older with relapsed or refractory acute leukemia. This recognition highlights the treatment's impact on aggressive acute myeloid and KMT2A-translocated leukemias.

Read more →
SNDX
Oct 30, 2026
SNDXConferences/Events

Syndax Announces Participation in November Investor Conferences

Syndax Pharmaceuticals announced its participation in several upcoming investor conferences. CEO Michael A. Metzger and the management team will engage in fireside chats at events in Boston, New York, and London from November 10 to November 19, 2026. Live webcasts of these sessions will be available on the company's website.

Read more →
SNDX
Oct 26, 2026
SNDXConferences/Events

Syndax to Announce Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 2, 2026

Syndax Pharmaceuticals plans to announce its third quarter 2026 financial results on November 2, 2026. The company will host a conference call and live audio webcast at 4:30 p.m. ET on the same day. A replay of the call will be available on their website for 90 days.

Read more →
SNDX
Oct 15, 2026
SNDXGeneral
▼ -5.5%on this news

Syndax’s Revuforj® (revumenib) Named to TIME’s Best Inventions of 2026 List

Syndax Pharmaceuticals announced that its menin inhibitor, Revuforj (revumenib), has been named one of TIME's Best Inventions of 2026 in the Medical and Healthcare category. This recognition highlights Revuforj's innovative approach in treating relapsed or refractory acute leukemia. The drug is the first approved menin inhibitor for both adults and children, showcasing its significant impact in oncology.

Read more →
SNDX
Oct 12, 2026
SNDXPhases
▼ -15.7%on this newsshared move

Syndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis

Syndax Pharmaceuticals announced that the MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis (IPF) did not meet its primary endpoint of annualized FVC decline. Despite the negative results, axatilimab demonstrated a safety profile consistent with previous studies. The company will not pursue further development of axatilimab for IPF but will continue its trials in chronic graft-versus-host disease (cGVHD).

Read more →
SNDX
Sep 1, 2026
SNDXConferences/Events

Syndax Announces Participation in September Investor Conferences

Syndax Pharmaceuticals announced its participation in two upcoming investor conferences in September 2026. CEO Michael A. Metzger and the management team will engage in fireside chats at the Citi Biopharma Conference and the H.C. Wainwright Global Investment Conference. Webcasts of these discussions will be accessible on the company's website.

Read more →
SNDX
Aug 4, 2026
SNDXGeneral

Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update

Syndax Pharmaceuticals reported second quarter 2026 total revenue of $73 million, marking a 92 percent year-over-year increase. Revuforj net revenue reached $54.7 million, up 91 percent from the prior year period. Niktimvo net revenue totaled $60.3 million, representing a 67 percent year-over-year rise. The company also highlighted expansion of its clinical pipeline with new assets targeting NSCLC and myelofibrosis.

Read more →
SNDX
Jul 28, 2026
SNDXConferences/Events

Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026

Syndax Pharmaceuticals announced it will report its second quarter 2026 financial results on August 4, 2026. The company will also host a conference call and live audio webcast at 4:30 p.m. ET on the same day. Investors can access the webcast through the company's website, with a replay available for 90 days post-event.

Read more →
SNDX
Jul 14, 2026
SNDXConferences/Events
▲ +5.4%on this news

Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event

Syndax Pharmaceuticals announced new pipeline assets during its R&D event today. The company selected SNDX-62122 for development in myelofibrosis and introduced SNDX-4321 for non-small cell lung cancer. A Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis is on track for topline data in the fourth quarter of 2026. These updates expand the firm's research portfolio with externally licensed and internally developed candidates.

Read more →
SNDX
Jun 11, 2026
SNDXPhases

Syndax Announces Publication of SAVE Data on Revuforj (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology

Syndax Pharmaceuticals announced promising data from the Phase 1/2 SAVE trial, showcasing high response rates for its all-oral therapy combining Revuforj, decitabine/cedazuridine, and venetoclax in treating relapsed or refractory AML patients with specific mutations. The trial demonstrated an overall response rate of 88%, with a significant portion of patients achieving minimal residual disease negativity and a robust transplant rate. The findings were published in the Journal of Clinical Oncology, indicating potential advancements in treatment standards for menin-dependent acute leukemias.

Read more →

About Syndax Pharmaceuticals, Inc.

New York, NY 298 employees syndax.com
Headquarters730 THIRD AVENUE, NEW YORK, NY, 10017
BIOPHARMAWATCH ELITE
Trade the next SNDX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime